Physician profile
Robert Youngblood
NPI 1447710207
$2,862.19
in general payments reported to CMS, 2019-2025
38 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,391 · 2022: $789 · 2023: $47.88 · 2024: $223 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $682.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $308.25 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Seagen INC. | $234.34 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $177.51 | 2021-2025 | |
| Amgen INC. | $165.42 | 2021-2022 | |
| Eisai INC. | $153.39 | 2021-2024 | |
| Astellas Pharma US INC | $151.21 | 2021-2025 | Vyloy |
| Astrazeneca Pharmaceuticals LP | $150.35 | 2021-2025 | Lynparza |
| Janssen Biotech, INC. | $133.79 | 2022-2025 | Darzalex, Imbruvica, Tecvayli |
| Incyte Corporation | $125.20 | 2021-2022 | |
| Pfizer INC. | $108.14 | 2021-2025 | |
| Lilly USA, LLC | $82.79 | 2021-2024 | Verzenio, Jaypirca |
| E.R. Squibb & Sons, L.L.C. | $81.59 | 2021-2022 | |
| Celgene Corporation | $71.69 | 2021-2022 | |
| Glaxosmithkline, LLC. | $69.83 | 2021 | |
| Abbvie INC. | $69.36 | 2024-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $68.97 | 2021-2022 | |
| Daiichi Sankyo INC. | $65.51 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.06 | 2021-2024 | |
| Taiho Oncology, INC. | $53.52 | 2025 | |
| Rigel Pharmaceuticals, INC. | $50.67 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $48.96 | 2021-2025 | Libtayo |
| Array Biopharma INC | $48.07 | 2021-2025 | Mektovi, Braftovi, Tukysa |
| Amag Pharmaceuticals, INC. | $43.73 | 2021 | |
| Genentech USA, INC. | $41.61 | 2022-2025 | Polivy |
| Coherus Oncology, INC. | $37.84 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.61 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $31.17 | 2021 | |
| Puma Biotechnology, INC. | $22.82 | 2022 | |
| Karyopharm Therapeutics INC. | $21.77 | 2025 | Xpovio |
| Emmaus Medical, INC. | $19.85 | 2021 | |
| Stemline Therapeutics INC. | $19.34 | 2025 | Orserdu |
| Blueprint Medicines Corporation | $19.25 | 2021 | |
| Exelixis INC. | $18.42 | 2024 | Cabometyx |
| Emd Serono, INC. | $17.54 | 2024 | |
| Tg Therapeutics, INC. | $13.89 | 2021 | |
| Dova Pharmaceuticals | $13.76 | 2021 | |
| Genmab U.S., INC. | $13.50 | 2025 | Epkinly |
| Sobi, INC | $12.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Youngblood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.